Fairmount Funds Management LLC
Fairmount Funds Management LLC reported 12 holdings worth US$1.51B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Fairmount Funds Management LLC reported 12 holdings worth US$1.51B as of Jun 30, 2026. Largest: Oruka Therapeutics, Inc., Dianthus Therapeutics, Inc. and Damora Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 12
- Value as reported
- US$1.51B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Oruka Therapeutics, Inc. | 3.71M | US$353M | 23.3% |
| Dianthus Therapeutics, Inc. | 2.54M | US$247M | 16.3% |
| Damora Therapeutics, Inc. | 8.71M | US$227M | 15.0% |
| Cogent Biosciences, Inc. | 5.5M | US$213M | 14.1% |
| Jade Biosciences, Inc. | 4.55M | US$101M | 6.7% |
| Enliven Therapeutics, Inc. | 1.86M | US$94.2M | 6.2% |
| Viridian Therapeutics, Inc. | 5.09M | US$93.5M | 6.2% |
| Zenas Biopharma, Inc. | 2.36M | US$59.9M | 4.0% |
| Crescent Biopharma, Inc. | 2.75M | US$49.5M | 3.3% |
| Apogee Therapeutics, Inc. | 299K | US$39.6M | 2.6% |
| Sensei Biotherapeutics, Inc. | 722K | US$18.1M | 1.2% |
| Inhibikase Therapeutics, Inc. | 8.63M | US$17.5M | 1.2% |
| Spyre Therapeutics, Inc. | 0 | US$0 | 0.00% |